Wajant; Harald

Patent Applications and Registrations

Patent applications and USPTO patent grants for Wajant; Harald.The latest application filed is for "tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcgr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcgr-independent agonistic activity; traaffiaa)".

Company Profile

3.12.14

Wajant; Harald - Kist DE
Wajant; Harald - Leinfelden-Echterdingen N/A DE
Wajant; Harald - Leinfelden DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antibodies to CD70 Grant 11,434,298 - Silence , et al. September 6, 2	2022-09-06
Antibodies to CD70 Grant 11,072,665 - Silence , et al. July 27, 2	2021-07-27
TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) App 20210079106 - Beilhack; Andreas ; et al.	2021-03-18
Antibodies To Cd70 App 20190270823 - Silence; Karen ; et al.	2019-09-05
Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines) Grant 9,944,708 - Pfizenmaier , et al. April 17, 2	2018-04-17
Antibodies To Cd70 App 20170369581 - SILENCE; Karen ; et al.	2017-12-28
Antibodies to CD70 Grant 9,765,148 - Silence , et al. September 19, 2	2017-09-19
Antibodies to CD70 Grant 9,765,149 - Silence , et al. September 19, 2	2017-09-19
Antibodies To Cd70 App 20150266963 - SILENCE; Karen ; et al.	2015-09-24
SITE-SPECIFIC ANTIBODY-MEDIATED ACTIVATION OF PROAPOPTOTIC CYTOKINES: AMAIZe (ANTIBODY-MEDIATED APOPTOSIS INDUCING CYTOKINES) App 20150152186 - Pfizenmaier; Klaus ; et al.	2015-06-04
Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) Grant 8,980,265 - Pfizenmaier , et al. March 17, 2	2015-03-17
Antibodies to CD70 Grant 8,834,882 - Silence , et al. September 16, 2	2014-09-16
Antibodies To Cd70 App 20140235843 - SILENCE; Karen ; et al.	2014-08-21
Antibodies To Cd70 App 20140147450 - SILENCE; Karen ; et al.	2014-05-29
Antibodies To Cd70 App 20140141016 - Silence; Karen ; et al.	2014-05-22
Process for producing hydroxynitrile lyases Grant 7,195,904 - Effenberger , et al. March 27, 2	2007-03-27
Selective local activation of members of the TNF receptor family by systemically inactive non-antibody TNF ligand fusion proteins App 20050244370 - Pfizenmaier, Klaus ; et al.	2005-11-03
Compositions and methods for treating trail-resistant cancer cells App 20040126791 - Wajant, Harald ; et al.	2004-07-01
Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) App 20040033511 - Pfizenmaier, Klaus ; et al.	2004-02-19
Process for producing hydroxynitrile lyases App 20030148440 - Effenberger, Franz ; et al.	2003-08-07
Method of producing (S)-cyanohydrins Grant 5,885,809 - Effenberger , et al. March 23, 1	1999-03-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.